About adalimumab
Tumor necrosis factor (TNF) blocker
Used for
- Rheumatoid, psoriatic, and juvenile idiopathic arthritis
- Ankylosing spondylitis and non-radiographic axial spondyloarthritis
- Plaque psoriasis and hidradenitis suppurativa
- Crohn’s disease and ulcerative colitis
Usual adult dose
Usually 40 mg under the skin every other week; some conditions require different schedules or doses.
Usual dose in children
For juvenile arthritis, commonly 10–40 mg under the skin every other week, depending on weight and age.
Common side effects
- Injection-site reactions
- Infections, including upper respiratory infections
- Headache
- Rash
Important warnings
- Can cause serious infections, including tuberculosis and fungal infections.
- Screen for tuberculosis before treatment; avoid live vaccines during treatment.
- May increase risk of certain cancers and rare blood or nervous-system disorders.
- Do not use with other TNF blockers or anakinra.
Pregnancy
May be used when clinically necessary; discuss risks and benefits with a healthcare professional. Exposure late in pregnancy may affect infant live-vaccine timing.
Breastfeeding
Generally considered compatible; small amounts may enter milk and are expected to be poorly absorbed by infants.
Interactions
- Other biologic immune suppressants, including abatacept and anakinra, increase infection risk.
- Live vaccines may cause infection during treatment.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.